Press Releases April 22, 2026 06:30 AM

BOSS Zhipin's Ongoing Share Repurchases Achieved Nearly RMB958 Million in 2026

KANZHUN LIMITED Accelerates Share Buyback Program With Nearly RMB958 Million Invested in 2026

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED, also known as BOSS Zhipin, has announced that it has repurchased shares worth nearly RMB958 million so far in 2026, including RMB27.2 million spent on April 21 alone. This continued buyback activity highlights the company's commitment to enhancing shareholder value.

BOSS Zhipin's Ongoing Share Repurchases Achieved Nearly RMB958 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED is actively repurchasing its shares in 2026, signaling confidence in its own stock valuation.
  • The company allocated nearly RMB958 million for share buybacks year-to-date, demonstrating a strong focus on shareholder returns.
  • This ongoing repurchase program may support the stock price and reflect management's positive outlook for future growth.

BEIJING, April 22, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing over RMB27.2 million to repurchase 579,118 ordinary shares on April 21. Year-to-date in 2026, the Company has deployed nearly RMB958 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Share repurchase programs can drain company cash reserves, potentially limiting investments in growth or operations, impacting the technology and employment sectors linked to BOSS Zhipin.
  • Market volatility or adverse business conditions could diminish the effectiveness of buybacks in supporting stock prices, affecting investor sentiment in the internet technology and recruitment sectors.
  • Regulatory or geopolitical risks related to cross-border listings (Nasdaq and Hong Kong) may add uncertainty to stock performance.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026